Evidence map›Paper›PMID 32115766›Full record

ArticlePediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology2020

Incidence, risk factors and re-exacerbation rate of severe asthma exacerbations in a multinational, multidatabase pediatric cohort study.

Marjolein Engelkes, Esme J Baan, Maria A J de Ridder, Elisabeth Svensson, Daniel Prieto-Alhambra, Francesco Lapi, Carlo Giaquinto, Gino Picelli, Nada Boudiaf, Frank Albers and 9 more

Abstract read
In one paragraph

Article in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Epidemiology of severe asthma in children: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2024
    Pooled it
  2. Risk factors for asthma exacerbations.The journal of allergy and clinical immunology. Global · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Asthma Exacerbations: The Genes Behind the Scenes.Journal of investigational allergology & clinical immunology · 2023
    Review
  13. Article
  14. Article
  15. Article
  16. Short-acting βPediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2022
    Article
  17. Article
  18. Sex differences in the relationship of sleep-disordered breathing and asthma control among children with severe asthma.The Journal of asthma : official journal of the Association for the Care of Asthma · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Marjolein EngelkesMedical Informatics, ErasmusMC, Rotterdam, The Netherlands.
Esme J BaanMedical Informatics, ErasmusMC, Rotterdam, The Netherlands.ORCID 0000-0002-0735-4296
Maria A J de RidderMedical Informatics, ErasmusMC, Rotterdam, The Netherlands.
Elisabeth SvenssonDepartment of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.
Daniel Prieto-AlhambraJordi Gol Primary Care Research Institute, Universitat Autonoma de Barcelona, Barcelona, Spain.
Francesco LapiSIMG, Florence, Italy.
Carlo GiaquintoUniversity of Padova, Padova, Italy.
Gino PicelliPedianet, Padova, Italy.
Nada BoudiafResearch and Development, GlaxoSmithKline, Middlesex, UK.
Frank AlbersResearch and Development, GlaxoSmithKline, Research Triangle Park, NC, USA.ORCID 0000-0001-7039-4621
Lee A EvittResearch and Development, GlaxoSmithKline, Brentford, UK.
Sarah CockleResearch and Development, GlaxoSmithKline, Brentford, UK.
Eric BradfordResearch and Development, GlaxoSmithKline, Brentford, UK.
Melissa K Van DykeResearch and Development, GlaxoSmithKline, Collegeville, PA, USA.ORCID 0000-0001-7246-2093
Robert SurukiUCB Biosciences, Raleigh, NC, USA.
Peter RijnbeekMedical Informatics, ErasmusMC, Rotterdam, The Netherlands.
Miriam C J M SturkenboomJulius Global Health, Utrecht University Medical Center, Utrecht, The Netherlands.
Hettie M JanssensPediatrics div Respiratory Medicine and Allergology, ErasmusMC- /Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Katia M C VerhammeMedical Informatics, ErasmusMC, Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are sparse real-world data on severe asthma exacerbations (SAE) in children. This multinational cohort study assessed the incidence of and risk factors for SAE and the incidence of asthma-related rehospitalization in children with asthma.

methodsAsthma patients 5-17 years old with ≥1 year of follow-up were identified in six European electronic databases from the Netherlands, Italy, the UK, Denmark and Spain in 2008-2013. Asthma was defined as ≥1 asthma-specific disease code within 3 months of prescriptions/dispensing of asthma medication. Severe asthma was defined as high-dosed inhaled corticosteroids plus a second controller. SAE was defined by systemic corticosteroids, emergency department visit and/or hospitalization all for reason of asthma. Risk factors for SAE were estimated by Poisson regression analyses.

resultsThe cohort consisted of 212 060 paediatric asthma patients contributing to 678 625 patient-years (PY). SAE rates ranged between 17 and 198/1000 PY and were higher in severe asthma and highest in severe asthma patients with a history of exacerbations. Prior SAE (incidence rate ratio 3-45) and younger age increased the SAE risk in all countries, whereas obesity, atopy and GERD were a risk factor in some but not all countries. Rehospitalization rates were up to 79% within 1 year.

conclusionsIn a real-world setting, SAE rates were highest in children with severe asthma with a history of exacerbations. Many severe asthma patients were rehospitalized within 1 year. Asthma management focusing on prevention of SAE is important to reduce the burden of asthma.

Indexed as

Anti-Asthmatic AgentsAsthmaAdolescentAdrenal Cortex HormonesChildChild, PreschoolCohort StudiesDisease ProgressionEuropeFemaleHumansIncidenceMaleRisk FactorsAdrenal Cortex HormonesAnti-Asthmatic Agentsasthma: epidemiologyasthma: risk factorsepidemiology: prevalence

Identifiers

PMID32115766
PMCPMC7496431

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.